Pharmacist Resources

Key Points for Pharmacists

  • The pharmacy certifies with Lenalidomide REMS
  • The certified pharmacy must obtain a confirmation number from Lenalidomide REMS before dispensing
  • The certified pharmacy counsels the patient, and completes the Education and Counseling Checklist
  • The certified pharmacy dispenses lenalidomide to patient along with a Medication Guide

Lenalidomide REMS information for certified pharmacies

Lenalidomide is only dispensed from Lenalidomide REMS certified pharmacies.

As a Lenalidomide REMS certified pharmacy, you must follow the requirements of Lenalidomide REMS. You may download a guide to the program, a checklist for counseling patients, and the full prescribing information below.

Pharmacy Guide to
Lenalidomide REMS

Full Prescribing Information

Education and Counseling
Checklist for Pharmacies

Lista de verificación de educación
y asesoramiento para farmacias

Pharmacy Portal for Celgene-administered REMS Programs

In addition to calling Lenalidomide REMS to obtain a confirmation number for a prescription, eligible pharmacies can obtain confirmation numbers using the Pharmacy Portal for Celgene-administered REMS Programs at CelgeneREMSPharmacyPortal.com. Contact Lenalidomide REMS to see if your pharmacy is eligible.

Pharmacy Portal for
Celgene-administered REMS Programs

Please report adverse drug experiences that are suspected to be associated with the use of lenalidomide and any suspected pregnancy occurring during the treatment with lenalidomide using any of the following methods:

REPORTING TO Lenalidomide REMS
Online: www.celgene.com/contact-us/
Email: drugsafety@celgene.com
Telephone: 1-908-673-9667
Toll-free: 1-800-640-7854 (Global Drug Safety & Risk Management) or
1-888-423-5436 (Lenalidomide REMS)
Fax: 1-908-673-9115
Mail to: Global Drug Safety & Risk Management
Celgene Corporation
86 Morris Avenue
Summit, New Jersey 07901

 

REPORTING TO THE FDA
Adverse drug experiences that are suspected to be associated with the use of lenalidomide and any suspected pregnancy occurring during the treatment with lenalidomide may also be reported to the FDA MedWatch Reporting System using any of the following methods:
Online: https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm
Telephone: 1-800-FDA-1088
Fax: 1-800-FDA-0178
Mail to: MedWatch
5600 Fishers Lane
Rockville, MD 20852-9787

For additional information about Lenalidomide REMS, please call 1-888-423-5436